Consistently, the combination of sorafenib with the eIF4E-eIF4G inhibitors 4E1RCat (structural) or 4EGI-1 (competitive) synergistically inhibits the cell viability and colony-formation ability of HCC cells [142]. This evidence concerns the gene EIF4E and hepatocellular carcinoma.